Bleeding Disorders Treatment - Global Market Outlook (2017-2026)

  • ID: 4480583
  • Report
  • Region: Global
  • 138 pages
  • Stratistics Market Research Consulting Pvt Ltd
1 of 4

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Baxalta (Now Shire)
  • Biogen Inc
  • CSL Behring
  • Janssen Pharmaceuticals
  • Octapharma
  • MORE
According to the publisher,The Global Bleeding Disorders Treatment Market is accounted for $11.14 billion in 2017 and expected to grow at a CAGR of 8.4% to reach $23.04 billion by 2026. factors like growth in R&D investment for hemophilia products, inclination to wards prophylactic treatment, increasing number of hemophilia patients, and the emergence of Biosimilars product are fuelling the market growth. Patent expiry of existing brands provide generic drug manufacturers an opportunity to enter, as well as sustaining healthcare infrastructure in developing economies with advancement in technology for development of new drugs and therapies will provide ample opportunity for the market growth. Market will also witness emerging trends like high entry barriers created by local government and low switching rate for hemophilia products. However, high cost of hemophilia drugs and inadequate reimbursement and lack of availability of skilled professionals are hampering the market growth.

By type, Hemophilia is a genetic disorder characterized by spontaneous hemorrhage or prolonged bleeding due to factor VIII or IX deficiency. Patients with more severe haemophilia suffer more severe and more frequent bleeds. Hemophilia is inherited in an X-linked recessive manner. The main therapy to treat hemophilia A is concentrated FVIII product, as clotting factor or simply factor. DDAVP (desmopressin acetate) is the synthetic version of vasopressin, a natural antidiuretic hormone that helps stop bleeding. Emerging trends in therapies are efficacy and safety assessments of established extended half-life (EHL) factor products and interest in Clinical trial data from new/emerging EHL factor products and nonfactor replacement therapies.

Based on Drug, Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. There are a few clotting factor concentrates that are rich in VWF. The management of patients affected by rare bleeding disorders (RBDs) is still a critical challenge. The development of alternative therapeutics, such as anti-tissue factor pathway inhibito r, ALN-AT3, and ACE910, for patients with hemophilia might also help in the treatment of patients affected by RBDs. FDA approved Vonvendi, which is produced with a genetically engineered Chinese hamster ovary cell line that expresses von Willebrand factor and the blood-clotting protein factor VIII.

North America is attributed to dominate the market during the forecast period owing to high acceptance for prophylaxis treatment among all age groups in the U.S. However, Asia Pacific is projected to grow at highest CAGR during the forecast period, due to increasing awareness of these disorders and availability of cheap generic drugs in the emerging economies such as India and China.

Some of the key players in Global Bleeding Disorders Treatment Market are Alnylam Pharmaceuticals, Amgen, Inc, Baxalta (Now Shire), Bayer Pharmaceuticals, Biogen Inc, Bristo l-Myers Squibb Company, Cangene Corporation, CSL Behring, Grifols SA, Janssen Pharmaceuticals, Nov-Nordisk A/S, Octapharma, Pfizer Inc., Sanofi and Xenetic Biosciences, Inc.

Drugs Covered:
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants
  • Plasma-derived Coagulation factor Concentrates
  • Recombinant Coagulation factor Concentrates
  • Other Drugs
Types Covered:
  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Clotting factor Deficiency
Therapies Covered:
  • Medication Treatments
  • Replacement Therapies
Regions Covered:
  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
  • South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa
What our report offers:
  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Baxalta (Now Shire)
  • Biogen Inc
  • CSL Behring
  • Janssen Pharmaceuticals
  • Octapharma
  • MORE
1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Futuristic Market Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Bleeding Disorders Treatment Market, By Drug
5.1 Introduction
5.2 Desmopressin
5.3 Antifibrinolytics
5.4 Fibrin Sealants
5.5 Plasma-derived Coagulation Factor Concentrates
5.5.1 Factor VIII
5.5.2 Factor IX
5.5.3 Factor for Von Willebrand Disease
5.5.4 Activated Prothrombin Complex Concentrate
5.6 Recombinant Coagulation Factor Concentrates
5.6.1 Factor VIII
5.6.2 Factor for Von Willebrand Disease
5.6.3 Factor IX
5.7 Other Drugs

6 Global Bleeding Disorders Treatment Market, By Type
6.1 Introduction
6.2 Hemophilia A
6.3 Hemophilia B
6.4 Von Willebrand Disease
6.5 Clotting Factor Deficiency

7 Global Bleeding Disorders Treatment Market, By Therapy
7.1 Introduction
7.2 Medication Treatments
7.2.1 Antifibrinolytic medicines
7.2.2 Iron supplementation
7.2.3 Desmopressin (DDAVP)
7.3 Replacement Therapies
7.3.1 Fresh frozen plasma transfusion therapy
7.3.2 Platelet transfusion therapy
7.3.3 Clotting factor replacement therapy

8 Global Bleeding Disorders Treatment Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa

9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling
10.1 Alnylam Pharmaceuticals
10.2 Amgen, Inc
10.3 Baxalta (Now Shire)
10.4 Bayer Pharmaceuticals
10.5 Biogen Inc
10.6 Bristol-Myers Squibb Company
10.7 Cangene Corporation
10.8 CSL Behring
10.9 Grifols SA
10.10 Janssen Pharmaceuticals
10.11 Novo Nordisk A/S
10.12 Octapharma
10.13 Pfizer Inc.
10.14 Sanofi
10.15 Xenetic Biosciences, Inc

List of Tables
Table 1 Global Bleeding Disorders Treatment Market Outlook, By Region (2016-2026) ($MN)
Table 2 Global Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 3 Global Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)
Table 4 Global Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)
Table 5 Global Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)
Table 6 Global Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
Table 7 Global Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 8 Global Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 9 Global Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 10 Global Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN)
Table 11 Global Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN)
Table 12 Global Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 13 Global Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 14 Global Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 15 Global Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)
Table 16 Global Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 17 Global Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)
Table 18 Global Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)
Table 19 Global Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN)
Table 20 Global Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN)
Table 21 Global Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)
Table 22 Global Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)
Table 23 Global Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN)
Table 24 Global Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)
Table 25 Global Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)
Table 26 Global Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)
Table 27 Global Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN)
Table 28 Global Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN)
Table 29 Global Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN)
Table 30 North America Bleeding Disorders Treatment Market Outlook, By Country (2016-2026) ($MN)
Table 31 North America Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 32 North America Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)
Table 33 North America Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)
Table 34 North America Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)
Table 35 North America Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
Table 36 North America Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 37 North America Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 38 North America Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 39 North America Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN)
Table 40 North America Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN)
Table 41 North America Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 42 North America Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 43 North America Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 44 North America Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)
Table 45 North America Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 46 North America Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)
Table 47 North America Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)
Table 48 North America Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN)
Table 49 North America Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN)
Table 50 North America Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)
Table 51 North America Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)
Table 52 North America Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN)
Table 53 North America Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)
Table 54 North America Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)
Table 55 North America Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)
Table 56 North America Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN)
Table 57 North America Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN)
Table 58 North America Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN)
Table 59 Europe Bleeding Disorders Treatment Market Outlook, By Country (2016-2026) ($MN)
Table 60 Europe Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 61 Europe Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)
Table 62 Europe Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)
Table 63 Europe Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)
Table 64 Europe Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
Table 65 Europe Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 66 Europe Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 67 Europe Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 68 Europe Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN)
Table 69 Europe Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN)
Table 70 Europe Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 71 Europe Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 72 Europe Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 73 Europe Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)
Table 74 Europe Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 75 Europe Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)
Table 76 Europe Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)
Table 77 Europe Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN)
Table 78 Europe Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN)
Table 79 Europe Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)
Table 80 Europe Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)
Table 81 Europe Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN)
Table 82 Europe Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)
Table 83 Europe Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)
Table 84 Europe Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)
Table 85 Europe Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN)
Table 86 Europe Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN)
Table 87 Europe Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN)
Table 88 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Country (2016-2026) ($MN)
Table 89 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 90 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)
Table 91 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)
Table 92 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)
Table 93 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
Table 94 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 95 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 96 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 97 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN)
Table 98 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN)
Table 99 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 100 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 101 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 102 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)
Table 103 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 104 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)
Table 105 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)
Table 106 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN)
Table 107 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN)
Table 108 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)
Table 109 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)
Table 110 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN)
Table 111 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)
Table 112 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)
Table 113 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)
Table 114 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN)
Table 115 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN)
Table 116 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN)
Table 117 South America Bleeding Disorders Treatment Market Outlook, By Country (2016-2026) ($MN)
Table 118 South America Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 119 South America Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)
Table 120 South America Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)
Table 121 South America Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)
Table 122 South America Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
Table 123 South America Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 124 South America Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 125 South America Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 126 South America Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN)
Table 127 South America Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN)
Table 128 South America Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 129 South America Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 130 South America Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 131 South America Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)
Table 132 South America Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 133 South America Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)
Table 134 South America Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)
Table 135 South America Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN)
Table 136 South America Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN)
Table 137 South America Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)
Table 138 South America Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)
Table 139 South America Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN)
Table 140 South America Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)
Table 141 South America Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)
Table 142 South America Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)
Table 143 South America Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN)
Table 144 South America Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN)
Table 145 South America Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN)
Table 146 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Country (2016-2026) ($MN)
Table 147 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 148 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)
Table 149 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)
Table 150 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)
Table 151 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
Table 152 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 153 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 154 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 155 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN)
Table 156 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN)
Table 157 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)
Table 158 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)
Table 159 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)
Table 160 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)
Table 161 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 162 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)
Table 163 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)
Table 164 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN)
Table 165 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN)
Table 166 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)
Table 167 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)
Table 168 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN)
Table 169 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)
Table 170 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)
Table 171 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)
Table 172 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN)
Table 173 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN)
Table 174 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Alnylam Pharmaceuticals
Amgen, Inc
Baxalta (Now Shire)
Bayer Pharmaceuticals
Biogen Inc
Bristol-Myers Squibb Company
Cangene Corporation
CSL Behring
Grifols SA
Janssen Pharmaceuticals
Novo Nordisk A/S
Octapharma
Pfizer Inc.
Sanofi
Xenetic Biosciences, Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll